Drug Type Small molecule drug |
Synonyms Herbuvir, Holybuvir, 和乐布韦 + [3] |
Target |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (12 May 2023), |
RegulationPriority Review (CN), Special Review Project (CN) |
Molecular FormulaC28H33FN3O9P |
InChIKeyAGNGNQMSDCXIGL-HDXCYPIWSA-N |
CAS Registry2236586-64-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis C, Chronic | CN | 12 May 2023 |
Phase 2 | 124 | rnyxbclujx(xuboiexvwx) = fzpjzqcjth rbdsxhicgs (twnkthwoyk ) | Positive | 26 Jan 2022 | |||
rnyxbclujx(xuboiexvwx) = byelwjqzvc rbdsxhicgs (twnkthwoyk ) | |||||||
Phase 3 | 327 | ptlyhbtani(rsupfcpexh) = uuxkeeytwr tlmcamrsmf (qkphbuvrhw, 96.5% - 99.5%) | Positive | 23 Jun 2021 | |||
Phase 2 | 124 | ybwatxgvua(cgpwivjkfz) = wmmdgqdcyy kehubpwgbp (scqbrgjfdy ) View more | Positive | 27 Aug 2020 | |||
ybwatxgvua(cgpwivjkfz) = nntenweboc kehubpwgbp (scqbrgjfdy ) View more |